KRAS and liver cancer: To experimentally validate therapeutic efficacy, we established orthotopic liver cancer models by transposon-mediated integration of Myc and Kras<sup>G12D</sup> oncogenes into hepatocytes of Trp53 null/null mice (pTMK/Trp53<sup>-/-</sup>), coupled with subcutaneous xenograft models.